US Therapeutic Plasma Exchange Market by Product (Devices, Consumables) Technology (Centrifugation, Membrane Separation) Procedures & Patients (Guillain Syndrome, Multiple Sclerosis, Cryoglobulinemia) End Users Covid-19 Impact - Forecast to 2025
The US therapeutic plasma exchange market is projected to reach USD 243 million by 2025 from USD 178 million in 2020, at a CAGR of 6.3% during the forecast period. Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period.
“The consumables segment to grow at the highest rate during the forecast period.”
On the basis of products, the US therapeutic plasma exchange market has been segmented into devices and consumables. The consumables segment witness the highest growth during the forecast period. The large share of this segment can be attributed to the recurrent use of these products, the increasing number of therapeutic plasma exchange procedures, and favorable reimbursement policies for TPE procedures.
“Advantages offered by centrifugation over membrane separation are driving market growth for centrifugation.”
On the basis of technology, the US therapeutic plasma exchange market has been segmented into centrifugation and membrane separation. In 2019, the centrifugation technology segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this segment can be attributed to the advantages offered by centrifugation over membrane separation, such as high efficiency and its ability to separate all types of blood components.
“Blood collection centers and blood component providers accounted for the largest share of the end user market “
On the basis of end user, the US therapeutic plasma exchange market has been segmented into blood
collection centers and blood component providers, hospitals and transfusion centers, and other end users. In 2019, the blood collection centers and blood component providers segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this end-user segment is mainly attributed to the rising number of blood component donations, the growing number of blood centers, and the increasing number of therapeutic plasma exchange procedures and plasma donations due to COVID-19.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage:
The report analyzes the market for various US therapeutic plasma exchange and their adoption pattern. It aims at estimating the market size and future growth potential of the US therapeutic plasma exchange market and different segments such as products, end user, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers:
“The consumables segment to grow at the highest rate during the forecast period.”
On the basis of products, the US therapeutic plasma exchange market has been segmented into devices and consumables. The consumables segment witness the highest growth during the forecast period. The large share of this segment can be attributed to the recurrent use of these products, the increasing number of therapeutic plasma exchange procedures, and favorable reimbursement policies for TPE procedures.
“Advantages offered by centrifugation over membrane separation are driving market growth for centrifugation.”
On the basis of technology, the US therapeutic plasma exchange market has been segmented into centrifugation and membrane separation. In 2019, the centrifugation technology segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this segment can be attributed to the advantages offered by centrifugation over membrane separation, such as high efficiency and its ability to separate all types of blood components.
“Blood collection centers and blood component providers accounted for the largest share of the end user market “
On the basis of end user, the US therapeutic plasma exchange market has been segmented into blood
collection centers and blood component providers, hospitals and transfusion centers, and other end users. In 2019, the blood collection centers and blood component providers segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this end-user segment is mainly attributed to the rising number of blood component donations, the growing number of blood centers, and the increasing number of therapeutic plasma exchange procedures and plasma donations due to COVID-19.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–30%, Tier 2–45%, and Tier 3–25%
- By Designation: C-level–35%, Director Level–25%, and Others–40%
Research Coverage:
The report analyzes the market for various US therapeutic plasma exchange and their adoption pattern. It aims at estimating the market size and future growth potential of the US therapeutic plasma exchange market and different segments such as products, end user, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the US therapeutic plasma exchange market
- Product & Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the US therapeutic plasma exchange market
- Market Development: Comprehensive information on the lucrative emerging regions by products, technology, indication, and end user
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the US therapeutic plasma exchange market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the US therapeutic plasma exchange market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY
TYPE AND DESIGNATION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (ILLUSTRATIVE EXAMPLE)
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
FIGURE 8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 9 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)
FIGURE 10 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 11 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
FIGURE 12 US THERAPEUTIC PLASMA EXCHANGE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
4.2.1 DRIVERS
4.2.1.1 Rising prevalence of chronic diseases
4.2.1.2 Technological advancements
4.2.2 RESTRAINTS
4.2.2.1 High cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model
4.2.3 OPPORTUNITIES
4.2.3.1 Therapeutic plasma exchange for pediatric patients
4.2.4 CHALLENGES
4.2.4.1 Dearth of skilled professionals
5 INDUSTRY INSIGHTS
5.1 INDUSTRY TRENDS
5.1.1 IMPACT OF COVID-19 ON THE THERAPEUTIC PLASMA EXCHANGE MARKET
FIGURE 13 IMPACT OF COVID-19 (2020-2025)
5.1.2 NEW INDICATIONS FOR PLASMA PRODUCTS
5.2 PORTER’S FIVE FORCES ANALYSIS
FIGURE 14 PORTER’S FIVE FORCES ANALYSIS (2019): US THERAPEUTIC PLASMA EXCHANGE MARKET
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 THREAT OF SUBSTITUTES
5.2.3 BARGAINING POWER OF SUPPLIERS
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 RIVALRY AMONG EXISTING COMPETITORS
5.3 VALUE CHAIN ANALYSIS
FIGURE 15 VALUE CHAIN: US THERAPEUTIC PLASMA EXCHANGE MARKET
5.4 REGULATORY ANALYSIS
5.4.1 US
6 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT & TECHNOLOGY
6.1 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT
6.1.1 INTRODUCTION
TABLE 2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
6.1.2 CONSUMABLES
6.1.2.1 Recurrent use of consumables to drive the growth of this segment
6.1.3 DEVICES
6.1.3.1 Increasing installation of devices in hospitals for therapeutic plasma exchange to drive market growth
6.2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY
6.2.1 INTRODUCTION
TABLE 3 CENTRIFUGATION VS. MEMBRANE SEPARATION
FIGURE 16 CENTRIFUGATION SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD
TABLE 4 THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
6.2.2 CENTRIFUGATION
6.2.2.1 Centrifugation technology to dominate the US therapeutic plasma exchange market
TABLE 5 KEY PRODUCTS OFFERED IN THE CENTRIFUGATION MARKET
6.2.3 MEMBRANE SEPARATION
6.2.3.1 Recent advances in developing highly permeable filters are supporting the growth of this market
TABLE 6 SIZE OF BLOOD COMPONENTS
TABLE 7 MEMBRANE SEPARATION PRODUCTS AVAILABLE IN THE MARKET
7 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 NEUROLOGICAL DISORDERS
7.2.1 NEUROLOGICAL DISORDERS ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019
TABLE 8 NEUROLOGICAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
7.2.1.1 Guillain–Barr? syndrome
7.2.1.1.1 Patient and procedure data for guillain-barr? syndrome
TABLE 9 DISEASE STATISTICS: GUILLAIN-BARR? SYNDROME
TABLE 10 TREATMENT GUIDELINES AND PROTOCOLS FOR GUILLAIN-BARR? SYNDROME
TABLE 11 EPIDEMIOLOGY FOR GUILLAIN-BARR? SYNDROME
7.2.1.2 Chronic inflammatory demyelinating polyneuropathy
7.2.1.2.1 Patient and procedure data for chronic inflammatory demyelinating polyneuropathy
TABLE 12 DISEASE STATISTICS: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
TABLE 13 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
TABLE 14 EPIDEMIOLOGY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
7.2.1.3 Myasthenia gravis
7.2.1.3.1 Patient and procedure data for myasthenia gravis
TABLE 15 DISEASE STATISTICS: MYASTHENIA GRAVIS
TABLE 16 TREATMENT GUIDELINES AND PROTOCOLS FOR MYASTHENIA GRAVIS
TABLE 17 EPIDEMIOLOGY FOR MYASTHENIA GRAVIS
7.2.1.4 Multiple sclerosis
7.2.1.4.1 Patient and procedure data for multiple sclerosis
TABLE 18 DISEASE STATISTICS: MULTIPLE SCLEROSIS
TABLE 19 TREATMENT GUIDELINES AND PROTOCOLS FOR MULTIPLE SCLEROSIS
TABLE 20 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS
TABLE 21 EPIDEMIOLOGY FOR MULTIPLE SCLEROSIS
7.2.1.5 PANDAS
7.2.1.5.1 Patient and procedure data for PANDAS
TABLE 22 DISEASE STATISTICS: PANDAS
TABLE 23 TREATMENT GUIDELINES AND PROTOCOLS FOR PANDAS
TABLE 24 EPIDEMIOLOGY FOR PANDAS
7.3 HEMATOLOGIC DISORDERS
7.3.1 INCREASING PREVALENCE AND INCIDENCE OF HEMATOLOGIC DISORDERS WILL BOOST THE DEMAND FOR THERAPEUTIC PLASMA EXCHANGE
TABLE 25 HEMATOLOGIC DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
7.3.1.1 Thrombotic thrombocytopenic purpura
7.3.1.1.1 Patient and procedure data for thrombotic thrombocytopenic purpura
TABLE 26 DISEASE STATISTICS: THROMBOTIC THROMBOCYTOPENIC PURPURA
TABLE 27 TREATMENT GUIDELINES AND PROTOCOLS FOR THROMBOTIC THROMBOCYTOPENIC PURPURA
TABLE 28 EPIDEMIOLOGY FOR THROMBOTIC THROMBOCYTOPENIC PURPURA
7.3.1.2 Atypical hemolytic uremic syndrome
7.3.1.2.1 Patient and procedure data for atypical hemolytic uremic syndrome
TABLE 29 DISEASE STATISTICS: ATYPICAL HEMOLYTIC UREMIC SYNDROME
TABLE 30 TREATMENT GUIDELINES AND PROTOCOL FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME
TABLE 31 EPIDEMIOLOGY FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME
7.3.1.3 Hyperviscosity syndrome
7.3.1.3.1 Patient and procedure data for hyperviscosity syndrome
TABLE 32 DISEASE STATISTICS: HYPERVISCOSITY SYNDROME
TABLE 33 TREATMENT GUIDELINES AND PROTOCOLS FOR HYPERVISCOSITY SYNDROME
TABLE 34 EPIDEMIOLOGY FOR HYPERVISCOSITY SYNDROME
7.3.1.4 Severe/symptomatic cryoglobulinemia
7.3.1.4.1 Patient and procedure data for cryoglobulinemia
TABLE 35 DISEASE STATISTICS: CRYOGLOBULINEMIA
TABLE 36 TREATMENT GUIDELINES AND PROTOCOLS FOR CRYOGLOBULINEMIA
TABLE 37 EPIDEMIOLOGY FOR CRYOGLOBULINEMIA
7.4 RENAL DISORDERS
7.4.1 THERAPEUTIC PLASMA EXCHANGE IS REGARDED AS ONE OF THE MOST USEFUL TREATMENT OPTIONS FOR SEVERAL RENAL DISORDERS
TABLE 38 RENAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
7.4.1.1 Goodpasture syndrome
7.4.1.1.1 Patient and procedure data for goodpasture syndrome
TABLE 39 DISEASE STATISTICS: GOODPASTURE SYNDROME
TABLE 40 TREATMENT GUIDELINES AND PROTOCOLS FOR GOODPASTURE SYNDROME
TABLE 41 EPIDEMIOLOGY FOR GOODPASTURE SYNDROME
7.4.1.2 WEGENER’S GRANULOMATOSIS (ANCA)-associated rapidly progressive glomerulonephritis
7.4.1.2.1 Patient and procedure data for wegener's granulomatosis
TABLE 42 DISEASE STATISTICS: WEGENER’S GRANULOMATOSIS
TABLE 43 TREATMENT GUIDELINES AND PROTOCOLS FOR WEGENER’S GRANULOMATOSIS
TABLE 44 EPIDEMIOLOGY FOR WEGENER’S GRANULOMATOSIS
7.4.1.3 Antibody-mediated renal transplant rejection
7.4.1.3.1 Patient and procedure data for AMR
TABLE 45 DISEASE STATISTICS: ANTIBODY?MEDIATED REJECTION
TABLE 46 TREATMENT GUIDELINES AND PROTOCOLS FOR ANTIBODY?MEDIATED REJECTION
TABLE 47 EPIDEMIOLOGY FOR ANTIBODY?MEDIATED REJECTION
7.5 METABOLIC DISORDERS
7.5.1 INCREASING ADOPTION OF PLASMA EXCHANGE FOR DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH
7.5.1.1 Familial hypercholesterolemia (homozygous)
7.5.1.1.1 Patient and procedure data for homozygous familial hypercholesterolemia
TABLE 48 DISEASE STATISTICS: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
TABLE 49 TREATMENT GUIDELINES AND PROTOCOLS FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
TABLE 50 EPIDEMIOLOGY FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
7.6 OTHER INDICATIONS
8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER
8.1 INTRODUCTION
FIGURE 17 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD
TABLE 51 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER, 2018–2025 (USD MILLION)
8.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
8.2.1 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS ARE THE LARGEST END USERS OF THERAPEUTIC PLASMA EXCHANGE
FIGURE 18 NUMBER OF ANNUAL PLASMA DONATIONS IN THE US, 2003?2016 (MILLION)
8.3 HOSPITALS & TRANSFUSION CENTERS
8.3.1 HOSPITALS & TRANSFUSION CENTERS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
8.4 OTHER END USERS
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
FIGURE 19 KEY DEVELOPMENTS IN THE US THERAPEUTIC PLASMA EXCHANGE MARKET, JANUARY 2017?JULY 2020
9.2 MARKET EVALUATION FRAMEWORK
FIGURE 20 MARKET EVALUATION FRAMEWORK: PRODUCT LAUNCHES & APPROVALS WERE THE MOST WIDELY ADOPTED STRATEGIES
9.3 COMPETITIVE SITUATIONS AND TRENDS
9.3.1 PRODUCT LAUNCHES & APPROVALS
9.3.2 EXPANSIONS
9.3.3 ACQUISITIONS
9.3.4 COLLABORATIONS
10 COMPANY EVALUATION MATRIX AND COMPANY PROFILES
10.1 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY
10.2 COMPETITIVE LEADERSHIP MAPPING
10.2.1 STARS
10.2.2 EMERGING LEADERS
10.2.3 PERVASIVE
10.2.4 EMERGING COMPANIES
FIGURE 21 US THERAPEUTIC PLASMA EXCHANGE MARKET: COMPETITIVE LEADERSHIP MAPPING (2019)
10.3 MARKET SHARE ANALYSIS
FIGURE 22 US THERAPEUTIC PLASMA EXCHANGE MARKET SHARE, BY KEY PLAYER, 2019
10.4 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, Strategic overview, Competitive analysis, MnM View)*
10.4.1 TERUMO BCT, INC.
FIGURE 23 TERUMO BCT, INC.: COMPANY SNAPSHOT (2018)
10.4.2 FRESENIUS SE & CO. KGAA
FIGURE 24 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2019)
FIGURE 25 FRESENIUS KABI: COMPANY SNAPSHOT (2019)
10.4.3 HAEMONETICS CORPORATION
FIGURE 26 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2020)
10.4.4 BAXTER INTERNATIONAL INC.
FIGURE 27 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2019)
10.4.5 ASAHI KASEI MEDICAL CO. LTD.
FIGURE 28 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019)
10.4.6 B. BRAUN MELSUNGEN AG
FIGURE 29 B. BRAUN MELSUNGEN: COMPANY SNAPSHOT (2019)
10.4.7 CERUS CORPORATION
FIGURE 30 CERUS CORPORATION: COMPANY SNAPSHOT (2019)
10.4.8 KANEKA CORPORATION
FIGURE 31 KANEKA CORPORATION: COMPANY SNAPSHOT (2019)
10.4.9 KAWASUMI LABORATORIES, INC.
FIGURE 32 KAWASUMI LABORATORIES: COMPANY SNAPSHOT (2019)
10.4.10 NIKKISO CO., LTD.
FIGURE 33 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2019)
10.4.11 MILTENYI BIOTEC
10.4.12 MEDICA S.P.A.
10.4.13 MEDICAP CLINIC GMBH
10.4.14 INFOMED
*Business Overview, Products Offered, Recent Developments, Strategic overview, Competitive analysis, MnM View might not be captured in case of unlisted companies.
11 APPENDIX
11.1 INSIGHTS OF INDUSTRY EXPERTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.4 AVAILABLE CUSTOMIZATIONS
11.5 RELATED REPORTS
11.6 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY
TYPE AND DESIGNATION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (ILLUSTRATIVE EXAMPLE)
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
FIGURE 8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 9 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)
FIGURE 10 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 11 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
FIGURE 12 US THERAPEUTIC PLASMA EXCHANGE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
4.2.1 DRIVERS
4.2.1.1 Rising prevalence of chronic diseases
4.2.1.2 Technological advancements
4.2.2 RESTRAINTS
4.2.2.1 High cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model
4.2.3 OPPORTUNITIES
4.2.3.1 Therapeutic plasma exchange for pediatric patients
4.2.4 CHALLENGES
4.2.4.1 Dearth of skilled professionals
5 INDUSTRY INSIGHTS
5.1 INDUSTRY TRENDS
5.1.1 IMPACT OF COVID-19 ON THE THERAPEUTIC PLASMA EXCHANGE MARKET
FIGURE 13 IMPACT OF COVID-19 (2020-2025)
5.1.2 NEW INDICATIONS FOR PLASMA PRODUCTS
5.2 PORTER’S FIVE FORCES ANALYSIS
FIGURE 14 PORTER’S FIVE FORCES ANALYSIS (2019): US THERAPEUTIC PLASMA EXCHANGE MARKET
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 THREAT OF SUBSTITUTES
5.2.3 BARGAINING POWER OF SUPPLIERS
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 RIVALRY AMONG EXISTING COMPETITORS
5.3 VALUE CHAIN ANALYSIS
FIGURE 15 VALUE CHAIN: US THERAPEUTIC PLASMA EXCHANGE MARKET
5.4 REGULATORY ANALYSIS
5.4.1 US
6 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT & TECHNOLOGY
6.1 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT
6.1.1 INTRODUCTION
TABLE 2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
6.1.2 CONSUMABLES
6.1.2.1 Recurrent use of consumables to drive the growth of this segment
6.1.3 DEVICES
6.1.3.1 Increasing installation of devices in hospitals for therapeutic plasma exchange to drive market growth
6.2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY
6.2.1 INTRODUCTION
TABLE 3 CENTRIFUGATION VS. MEMBRANE SEPARATION
FIGURE 16 CENTRIFUGATION SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD
TABLE 4 THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)
6.2.2 CENTRIFUGATION
6.2.2.1 Centrifugation technology to dominate the US therapeutic plasma exchange market
TABLE 5 KEY PRODUCTS OFFERED IN THE CENTRIFUGATION MARKET
6.2.3 MEMBRANE SEPARATION
6.2.3.1 Recent advances in developing highly permeable filters are supporting the growth of this market
TABLE 6 SIZE OF BLOOD COMPONENTS
TABLE 7 MEMBRANE SEPARATION PRODUCTS AVAILABLE IN THE MARKET
7 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 NEUROLOGICAL DISORDERS
7.2.1 NEUROLOGICAL DISORDERS ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019
TABLE 8 NEUROLOGICAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
7.2.1.1 Guillain–Barr? syndrome
7.2.1.1.1 Patient and procedure data for guillain-barr? syndrome
TABLE 9 DISEASE STATISTICS: GUILLAIN-BARR? SYNDROME
TABLE 10 TREATMENT GUIDELINES AND PROTOCOLS FOR GUILLAIN-BARR? SYNDROME
TABLE 11 EPIDEMIOLOGY FOR GUILLAIN-BARR? SYNDROME
7.2.1.2 Chronic inflammatory demyelinating polyneuropathy
7.2.1.2.1 Patient and procedure data for chronic inflammatory demyelinating polyneuropathy
TABLE 12 DISEASE STATISTICS: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
TABLE 13 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
TABLE 14 EPIDEMIOLOGY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
7.2.1.3 Myasthenia gravis
7.2.1.3.1 Patient and procedure data for myasthenia gravis
TABLE 15 DISEASE STATISTICS: MYASTHENIA GRAVIS
TABLE 16 TREATMENT GUIDELINES AND PROTOCOLS FOR MYASTHENIA GRAVIS
TABLE 17 EPIDEMIOLOGY FOR MYASTHENIA GRAVIS
7.2.1.4 Multiple sclerosis
7.2.1.4.1 Patient and procedure data for multiple sclerosis
TABLE 18 DISEASE STATISTICS: MULTIPLE SCLEROSIS
TABLE 19 TREATMENT GUIDELINES AND PROTOCOLS FOR MULTIPLE SCLEROSIS
TABLE 20 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS
TABLE 21 EPIDEMIOLOGY FOR MULTIPLE SCLEROSIS
7.2.1.5 PANDAS
7.2.1.5.1 Patient and procedure data for PANDAS
TABLE 22 DISEASE STATISTICS: PANDAS
TABLE 23 TREATMENT GUIDELINES AND PROTOCOLS FOR PANDAS
TABLE 24 EPIDEMIOLOGY FOR PANDAS
7.3 HEMATOLOGIC DISORDERS
7.3.1 INCREASING PREVALENCE AND INCIDENCE OF HEMATOLOGIC DISORDERS WILL BOOST THE DEMAND FOR THERAPEUTIC PLASMA EXCHANGE
TABLE 25 HEMATOLOGIC DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
7.3.1.1 Thrombotic thrombocytopenic purpura
7.3.1.1.1 Patient and procedure data for thrombotic thrombocytopenic purpura
TABLE 26 DISEASE STATISTICS: THROMBOTIC THROMBOCYTOPENIC PURPURA
TABLE 27 TREATMENT GUIDELINES AND PROTOCOLS FOR THROMBOTIC THROMBOCYTOPENIC PURPURA
TABLE 28 EPIDEMIOLOGY FOR THROMBOTIC THROMBOCYTOPENIC PURPURA
7.3.1.2 Atypical hemolytic uremic syndrome
7.3.1.2.1 Patient and procedure data for atypical hemolytic uremic syndrome
TABLE 29 DISEASE STATISTICS: ATYPICAL HEMOLYTIC UREMIC SYNDROME
TABLE 30 TREATMENT GUIDELINES AND PROTOCOL FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME
TABLE 31 EPIDEMIOLOGY FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME
7.3.1.3 Hyperviscosity syndrome
7.3.1.3.1 Patient and procedure data for hyperviscosity syndrome
TABLE 32 DISEASE STATISTICS: HYPERVISCOSITY SYNDROME
TABLE 33 TREATMENT GUIDELINES AND PROTOCOLS FOR HYPERVISCOSITY SYNDROME
TABLE 34 EPIDEMIOLOGY FOR HYPERVISCOSITY SYNDROME
7.3.1.4 Severe/symptomatic cryoglobulinemia
7.3.1.4.1 Patient and procedure data for cryoglobulinemia
TABLE 35 DISEASE STATISTICS: CRYOGLOBULINEMIA
TABLE 36 TREATMENT GUIDELINES AND PROTOCOLS FOR CRYOGLOBULINEMIA
TABLE 37 EPIDEMIOLOGY FOR CRYOGLOBULINEMIA
7.4 RENAL DISORDERS
7.4.1 THERAPEUTIC PLASMA EXCHANGE IS REGARDED AS ONE OF THE MOST USEFUL TREATMENT OPTIONS FOR SEVERAL RENAL DISORDERS
TABLE 38 RENAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
7.4.1.1 Goodpasture syndrome
7.4.1.1.1 Patient and procedure data for goodpasture syndrome
TABLE 39 DISEASE STATISTICS: GOODPASTURE SYNDROME
TABLE 40 TREATMENT GUIDELINES AND PROTOCOLS FOR GOODPASTURE SYNDROME
TABLE 41 EPIDEMIOLOGY FOR GOODPASTURE SYNDROME
7.4.1.2 WEGENER’S GRANULOMATOSIS (ANCA)-associated rapidly progressive glomerulonephritis
7.4.1.2.1 Patient and procedure data for wegener's granulomatosis
TABLE 42 DISEASE STATISTICS: WEGENER’S GRANULOMATOSIS
TABLE 43 TREATMENT GUIDELINES AND PROTOCOLS FOR WEGENER’S GRANULOMATOSIS
TABLE 44 EPIDEMIOLOGY FOR WEGENER’S GRANULOMATOSIS
7.4.1.3 Antibody-mediated renal transplant rejection
7.4.1.3.1 Patient and procedure data for AMR
TABLE 45 DISEASE STATISTICS: ANTIBODY?MEDIATED REJECTION
TABLE 46 TREATMENT GUIDELINES AND PROTOCOLS FOR ANTIBODY?MEDIATED REJECTION
TABLE 47 EPIDEMIOLOGY FOR ANTIBODY?MEDIATED REJECTION
7.5 METABOLIC DISORDERS
7.5.1 INCREASING ADOPTION OF PLASMA EXCHANGE FOR DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH
7.5.1.1 Familial hypercholesterolemia (homozygous)
7.5.1.1.1 Patient and procedure data for homozygous familial hypercholesterolemia
TABLE 48 DISEASE STATISTICS: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
TABLE 49 TREATMENT GUIDELINES AND PROTOCOLS FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
TABLE 50 EPIDEMIOLOGY FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
7.6 OTHER INDICATIONS
8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER
8.1 INTRODUCTION
FIGURE 17 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD
TABLE 51 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER, 2018–2025 (USD MILLION)
8.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
8.2.1 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS ARE THE LARGEST END USERS OF THERAPEUTIC PLASMA EXCHANGE
FIGURE 18 NUMBER OF ANNUAL PLASMA DONATIONS IN THE US, 2003?2016 (MILLION)
8.3 HOSPITALS & TRANSFUSION CENTERS
8.3.1 HOSPITALS & TRANSFUSION CENTERS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
8.4 OTHER END USERS
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
FIGURE 19 KEY DEVELOPMENTS IN THE US THERAPEUTIC PLASMA EXCHANGE MARKET, JANUARY 2017?JULY 2020
9.2 MARKET EVALUATION FRAMEWORK
FIGURE 20 MARKET EVALUATION FRAMEWORK: PRODUCT LAUNCHES & APPROVALS WERE THE MOST WIDELY ADOPTED STRATEGIES
9.3 COMPETITIVE SITUATIONS AND TRENDS
9.3.1 PRODUCT LAUNCHES & APPROVALS
9.3.2 EXPANSIONS
9.3.3 ACQUISITIONS
9.3.4 COLLABORATIONS
10 COMPANY EVALUATION MATRIX AND COMPANY PROFILES
10.1 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY
10.2 COMPETITIVE LEADERSHIP MAPPING
10.2.1 STARS
10.2.2 EMERGING LEADERS
10.2.3 PERVASIVE
10.2.4 EMERGING COMPANIES
FIGURE 21 US THERAPEUTIC PLASMA EXCHANGE MARKET: COMPETITIVE LEADERSHIP MAPPING (2019)
10.3 MARKET SHARE ANALYSIS
FIGURE 22 US THERAPEUTIC PLASMA EXCHANGE MARKET SHARE, BY KEY PLAYER, 2019
10.4 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, Strategic overview, Competitive analysis, MnM View)*
10.4.1 TERUMO BCT, INC.
FIGURE 23 TERUMO BCT, INC.: COMPANY SNAPSHOT (2018)
10.4.2 FRESENIUS SE & CO. KGAA
FIGURE 24 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2019)
FIGURE 25 FRESENIUS KABI: COMPANY SNAPSHOT (2019)
10.4.3 HAEMONETICS CORPORATION
FIGURE 26 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2020)
10.4.4 BAXTER INTERNATIONAL INC.
FIGURE 27 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2019)
10.4.5 ASAHI KASEI MEDICAL CO. LTD.
FIGURE 28 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019)
10.4.6 B. BRAUN MELSUNGEN AG
FIGURE 29 B. BRAUN MELSUNGEN: COMPANY SNAPSHOT (2019)
10.4.7 CERUS CORPORATION
FIGURE 30 CERUS CORPORATION: COMPANY SNAPSHOT (2019)
10.4.8 KANEKA CORPORATION
FIGURE 31 KANEKA CORPORATION: COMPANY SNAPSHOT (2019)
10.4.9 KAWASUMI LABORATORIES, INC.
FIGURE 32 KAWASUMI LABORATORIES: COMPANY SNAPSHOT (2019)
10.4.10 NIKKISO CO., LTD.
FIGURE 33 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2019)
10.4.11 MILTENYI BIOTEC
10.4.12 MEDICA S.P.A.
10.4.13 MEDICAP CLINIC GMBH
10.4.14 INFOMED
*Business Overview, Products Offered, Recent Developments, Strategic overview, Competitive analysis, MnM View might not be captured in case of unlisted companies.
11 APPENDIX
11.1 INSIGHTS OF INDUSTRY EXPERTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.4 AVAILABLE CUSTOMIZATIONS
11.5 RELATED REPORTS
11.6 AUTHOR DETAILS
